Skip to main content
Press Releases

Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program

SAN DIEGO, July 20, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today provided an update on the status of its ongoing CD388 program for prevention of influenza A and B, which is the subject of an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson &…
wpengine
July 20, 2023
Press Releases

Cidara Therapeutics Added to Russell Microcap® Index

SAN DIEGO, June 26, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, announced today it has joined the broad market Russell Microcap® Index at the conclusion of the Russell U.S. Indexes annual reconstitution. The newly reconstituted Index will become effective after the U.S. equity market opens on Monday, June 26, 2023. Annual Russell indexes reconstitution…
wpengine
June 26, 2023
Press Releases

Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

SAN DIEGO, June 22, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CD388, Cidara's novel drug-Fc conjugate (DFC) candidate. CD388 is being developed in collaboration with Janssen Pharmaceuticals for the prevention of influenza A and B infection in adults…
wpengine
June 22, 2023
Press Releases

Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit

SAN DIEGO, June 20, 2023 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting drug-Fc conjugate (DFC), as well as the development of its novel DFCs from Cidara's Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy…
wpengine
June 20, 2023
Press Releases

Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit

SAN DIEGO, June 13, 2023 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting DFC candidate, as well as the development of its novel drug-Fc conjugates (DFCs) from Cidara's Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer…
wpengine
June 13, 2023
Press Releases

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

SAN DIEGO, May 11, 2023 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an update on its corporate activities and product pipeline. "The recently received $20.0 million milestone payment from Melinta Therapeutics following the U.S. Food and Drug Administration (FDA) approval of…
wpengine
May 11, 2023
Press Releases

Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference

- Oral presentations demonstrate positive preclinical data highlighting CD388's activity against influenza A and B -SAN DIEGO, May 03, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, is delivering two oral presentations highlighting new preclinical data on its novel drug-Fc conjugate (DFC) candidate targeting influenza A and B, CD388, at the 7th International Society for…
wpengine
May 3, 2023
Press Releases

Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™

- U.S. launch of REZZAYO by Melinta expected in mid-2023 -- Company eligible to receive up to an additional $47 million in milestones from multiple existing partnerships based on successful completion of activities planned over the next year - SAN DIEGO, April 24, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced receipt of…
wpengine
April 24, 2023
Press Releases

Cidara Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, March 31, 2023 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, is scheduled to participate in the following upcoming investor conferences. Event: Cantor Fitzgerald Future of Oncology Virtual SymposiumFormat: Panel DiscussionDate: Monday, April 3, 2023Time: 11:00am ET Event: 22nd Annual Needham Virtual Healthcare ConferenceFormat: Presentation and…
wpengine
March 31, 2023
Press Releases

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

SAN DIEGO, March 23, 2023 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December 31, 2022 and provided an update on its corporate activities and product pipeline. "We have completed a transformational 2022 for Cidara and are carrying that momentum into 2023 with the recent U.S.…
wpengine
March 23, 2023